Verbatim response from ChatGPT
Short answer: many people do regain at least some weight after stopping GLP‑1 receptor agonists. How much and how fast depends on why you were taking them, what other changes you keep up, and your metabolism.
Why that happens
- GLP‑1s (examples: Wegovy and Ozempic — semaglutide; Saxenda — liraglutide; Mounjaro/Zepbound — tirzepatide) reduce appetite, slow gastric emptying, and change hunger signaling. When the drug is stopped, appetite and hunger signals commonly return toward pre‑treatment levels.
- There’s also metabolic adaptation (lower resting energy expenditure after weight loss), so the body defends a higher weight. Clinical trials (for example STEP for semaglutide, SCALE for liraglutide, SURMOUNT for tirzepatide) show substantial weight is often regained after stopping treatment.
Typical timeline and magnitude
- Appetite can increase within weeks. Weight regain often appears over months and can continue unless countermeasures are taken. Some people regain most lost weight; others keep part of it if they’ve adopted lasting diet, activity, and behavioral changes.
What to do if you’re thinking of stopping
- Talk to the prescriber first — especially if you have diabetes. Stopping can raise blood sugar and may require adjustments to insulin or other drugs.
- Consider a plan instead of an abrupt stop: schedule follow‑up, increase monitoring (weights, glucose/A1c), and get support for lifestyle maintenance. (There’s limited evidence that tapering prevents regain; the key is the follow‑up plan.)
- Intensify non‑drug measures that help maintain weight: a high‑protein/controlled‑calorie diet, regular aerobic + resistance exercise, frequent self‑weighing, and behavioral counseling or cognitive‑behavioral therapy.
Other medical options
- If stopping one GLP‑1, discuss alternatives with your clinician (e.g., switching to another agent or combining therapies). Other prescription options for weight management include: orlistat, bupropion‑naltrexone (Contrave), and newer agents like tirzepatide (Zepbound for weight management; Mounjaro for diabetes). An obesity medicine specialist can advise on combinations and long‑term strategy.
Who can help
- Your prescribing clinician or an obesity medicine specialist (look for American Board of Obesity Medicine certification).
- Registered dietitian (RD/RDN) for a sustainable eating plan.
- Structured programs with evidence: the CDC‑recognized Diabetes Prevention Program (DPP) for metabolic health; commercial programs such as WW (WeightWatchers) or medically supervised weight‑management clinics for ongoing support. Digital behavior programs (e.g., Noom) can help some people but results vary.
Bottom line
- Stopping GLP‑1s often leads to increased hunger and a high risk of weight regain unless you have strong, sustained lifestyle and behavioral strategies or an alternative medical plan in place. Before you stop, talk with your clinician to set up monitoring, adjust medications if needed, and arrange ongoing support.
If you want, tell me which GLP‑1 you’re on (brand/dose) and why you’re thinking of stopping, and I can help draft questions to ask your provider or suggest a stepwise plan.